pt. 1. General considerations -- pt. 2. The epidemiological impact of toxic episodes -- pt. 3. Diversity of marine toxins as pharmacological tools -- pt. 4. Paralytic shellfish poisoning (PSP) -- pt. 5. Diarrheic episodes : phosphatase inhibitors -- pt. 6. Lipophyllic toxins : nonphosphatase inhibitors -- pt. 6A. Yessotoxins -- pt. 6B. Pectenotoxins -- pt. 7. Domoic acid intoxication -- pt. 8. Non-PSP neurotoxic episodes -- pt. 8A. Ciguatera toxins -- pt. 8B. Maitotoxin -- pt. 8C. Brevetoxins -- pt. 8D. Cyclic imines -- pt. 8E. Polycavernosides and gambierol -- pt. 9. Palytoxin, ostreocin, ovatatoxin -- pt. 10. Pfiesteria toxins -- pt. 11. Azaspiracids -- pt. 12. Cyanobacterial toxins -- pt. 12A. Neurotoxins -- pt. 12B. Hepatotoxins -- pt. 13. Toxins as a starting point to drugs -- pt. 14. Legal and economic views.